

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 April 2006 (13.04.2006)

PCT

(10) International Publication Number
WO 2006/037787 A3

(51) International Patent Classification:

A61K 39/00 (2006.01) A61K 39/39 (2006.01)

(21) International Application Number:

PCT/EP2005/055009

(22) International Filing Date: 5 October 2005 (05.10.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/615,637 5 October 2004 (05.10.2004) US
05105228.0 14 June 2005 (14.06.2005) EP

(71) Applicant (for all designated States except US): **CYTOS BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 25, CH-8952 Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BACHMANN, Martin** [CH/CH]; Cytos Biotechnology AG, Goldackerweg 8, CH-8472 Seuzach (CH). **MAURER, Patrik** [DE/CH]; Cytos Biotechnology AG, Rychenbergstrasse 38, CH-8400 Winterthur (CH). **MEIJERINK, Edwin** [NL/CH]; Cytos Biotechnology AG, Rebbergstrasse 50, CH-8049 Zürich (CH). **PROBA, Karl** [DE/CH]; Cytos Biotechnology AG, Tramstrasse 95, CH-8050 Zürich (CH). **SCHWARZ, Katrin** [DE/CH]; Cytos Biotechnology AG, Alter Zürichweg 31, CH-8952 Schlieren (CH).

(74) Agent: **SPERRLE, Martin**; Cytos Biotechnology AG, IP & Legal Affairs, Wagistrasse 25, CH-8952 Schlieren (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:

6 July 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VLP-ANTIGEN CONJUGATES AND THEIR USES AS VACCINES

(57) Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with secondary structure comprised by the VLP is at most 20% of the amount of host RNA with secondary structure originally comprised by the VLP; and wherein the VLP and the at least one antigen are linked with one another. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in the production of vaccines for the treatment of diseases, disorders and conditions. Furthermore, the compositions of the invention are particularly useful to efficiently induce strong antibody responses against the antigen within the indicated context while lowering or eliminating unwanted T cell responses.

WO 2006/037787 A3